VOXCAN, along with BioSystems Technology, BioVersys join forces to establish IMPACT2 – a breakthrough innovative translation AMR platform that will expedite the development of novel new medecine in the fight against antimicrobial resistance – a joint programme co-funded by EUREKA member countries and the European Union Horizon 2020 Framework Programme.
